Literature DB >> 24021925

Lactational exposure to sulpiride: assessment of maternal care and reproductive and behavioral parameters of male rat pups.

Milene Leivas Vieira1, Alice Hartmann Dos Santos, Luiza Sienna Silva, Glaura Scantamburlo Alves Fernandes, Ana Carolina Inhasz Kiss, Estefânia Gastaldello Moreira, Suzana de Fátima Paccola Mesquita, Daniela Cristina Ceccatto Gerardin.   

Abstract

Dopaminergic receptor antagonists may be used as galactagogues because they increase serum prolactin (PRL) by counteracting the inhibitory influence of dopamine on PRL secretion. The antipsychotic drug sulpiride (SUL) is documented to be effective as a galactagogue, but it is transferred through milk to the neonates. The aim of the present study was to evaluate if maternal exposure to SUL during lactation could disrupt maternal care and/or male offspring reproductive development. The dams were treated daily (gavage) with SUL 2.5mg/kg or 25mg/kg during lactation. Maternal behavior was analyzed on lactational days 5 and 10. In offspring, reproductive and behavioral parameters were analyzed at different time points. SUL treatment did not impair maternal care, but caused testicular damage in male offspring. At postnatal day 90, a reduction in testis weight, volume of seminiferous tubule and histopathological alterations such as an increased percentage of abnormal seminiferous tubules were observed. Data shows that maternal exposure to SUL during lactation may impact the reproductive development of male rats and the testes seem to be the main target organ at adulthood.
© 2013.

Entities:  

Keywords:  Dopaminergic receptor antagonist; Galactagogue; Prostate; Testis

Mesh:

Substances:

Year:  2013        PMID: 24021925     DOI: 10.1016/j.physbeh.2013.08.027

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  1 in total

Review 1.  Psychoactive drug exposure during breastfeeding: a critical need for preclinical behavioral testing.

Authors:  Irving Zucker
Journal:  Psychopharmacology (Berl)       Date:  2018-03-16       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.